[Usefulness of PET in clinical trials of psychotropic drugs].
Suhara
Tetsuya
T
Morimoto
Takuya
T
D001665:Binding Sites; D001921:Brain / Q000378:metabolism; D002986:Clinical Trials as Topic; D015195:Drug Design; D006801:Humans; D008024:Ligands; D008562:Membrane Glycoproteins / Q000378:metabolism; D026901:Membrane Transport Proteins / Q000378:metabolism; D001523:Mental Disorders / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000378:metabolism; D049268:Positron-Emission Tomography; D011619:Psychotropic Drugs / Q000008:administration & dosage* / Q000378:metabolism* / Q000493:pharmacokinetics; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D050486:Serotonin Plasma Membrane Transport Proteins; D016896:Treatment Outcome
D008024:Ligands; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D011619:Psychotropic Drugs; D017448:Receptors, Dopamine D2; C493230:SLC6A4 protein, human; D050486:Serotonin Plasma Membrane Transport Proteins